Cochlear Ltd (CHEOF)
176.25
-5.75
(-3.16%)
USD |
OTCM |
Dec 13, 16:00
Price Chart
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 11.54B |
| 52 Week High (Daily) | Upgrade |
| 52 Week Low (Daily) | Upgrade |
| All-Time High (Daily) | Upgrade |
| Year to Date Total Returns (Daily) | Upgrade |
| 1 Month Total Returns (Daily) | Upgrade |
| 1 Year Total Returns (Daily) | -10.67% |
| Valuation | |
| PE Ratio | 49.56 |
| PE Ratio (Forward) | Upgrade |
| PS Ratio | 7.905 |
| Price to Book Value | 9.378 |
| EV to EBITDA | Upgrade |
| Dividend | |
|---|---|
| Dividend | 1.418 |
| Dividend Yield (Forward) | Upgrade |
| Financials | |
| Revenue (5 Year Growth) | Upgrade |
| Revenue (Quarterly YoY Growth) | Upgrade |
| EPS Diluted (5 Year Growth) | Upgrade |
| EPS Diluted (Quarterly YoY Growth) | Upgrade |
| Debt to Equity Ratio | 0.00 |
| Return on Equity | Upgrade |
| Return on Assets | Upgrade |
| Risk | |
| Beta (5Y) | Upgrade |
| Max Drawdown (5Y) | 41.54% |
Profile
| Cochlear is the leading cochlear implant device manufacturer with around 60% global market share. Developed markets contribute 80% of group revenue where cochlear implants are the standard of care for children with severe to profound hearing loss. The company also actively targets the growing cohort of seniors in developed markets. Tender-oriented emerging markets contribute the remaining 20% of group revenue. Main products include cochlear implants, bone-anchored hearing aids, and associated sound processors. In fiscal 2020, 49% of revenue came from the Americas, 35% from Europe, the Middle East, and Africa, and 16% from the Asia-Pacific segment. |
| URL | https://www.cochlear.com |
| Investor Relations URL | N/A |
| HQ State/Province | N/A |
| Sector | Health Care |
| Industry | Health Care Equipment & Supplies |
| Equity Style | Large Cap/Growth |
| Next Earnings Release | Feb. 19, 2025 (est.) |
| Last Earnings Release | Aug. 15, 2024 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | Sep. 17, 2024 |
Ratings
Profile
| Cochlear is the leading cochlear implant device manufacturer with around 60% global market share. Developed markets contribute 80% of group revenue where cochlear implants are the standard of care for children with severe to profound hearing loss. The company also actively targets the growing cohort of seniors in developed markets. Tender-oriented emerging markets contribute the remaining 20% of group revenue. Main products include cochlear implants, bone-anchored hearing aids, and associated sound processors. In fiscal 2020, 49% of revenue came from the Americas, 35% from Europe, the Middle East, and Africa, and 16% from the Asia-Pacific segment. |
| URL | https://www.cochlear.com |
| Investor Relations URL | N/A |
| HQ State/Province | N/A |
| Sector | Health Care |
| Industry | Health Care Equipment & Supplies |
| Equity Style | Large Cap/Growth |
| Next Earnings Release | Feb. 19, 2025 (est.) |
| Last Earnings Release | Aug. 15, 2024 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | Sep. 17, 2024 |